U.S. markets closed
  • S&P 500

    4,662.85
    +3.82 (+0.08%)
     
  • Dow 30

    35,911.81
    -201.79 (-0.56%)
     
  • Nasdaq

    14,893.75
    +86.95 (+0.59%)
     
  • Russell 2000

    2,162.46
    +3.02 (+0.14%)
     
  • Crude Oil

    84.30
    +0.48 (+0.57%)
     
  • Gold

    1,818.90
    +2.40 (+0.13%)
     
  • Silver

    23.03
    +0.12 (+0.51%)
     
  • EUR/USD

    1.1409
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    1.7720
    +0.0610 (+3.57%)
     
  • GBP/USD

    1.3645
    -0.0035 (-0.26%)
     
  • USD/JPY

    114.5800
    +0.3800 (+0.33%)
     
  • BTC-USD

    41,921.54
    -1,071.39 (-2.49%)
     
  • CMC Crypto 200

    1,005.40
    -20.33 (-1.98%)
     
  • FTSE 100

    7,611.23
    +68.28 (+0.91%)
     
  • Nikkei 225

    28,333.52
    +209.24 (+0.74%)
     

Is This Latecomer a Better Buy Than Moderna and Pfizer?

·4 min read
Is This Latecomer a Better Buy Than Moderna and Pfizer?
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) dominate the coronavirus vaccine market. Johnson & Johnson also sells a coronavirus vaccine. The U.S. awarded the biotech $1.6 billion in funding in the early days of the vaccine race -- and a contract for the delivery of 100 million vaccine doses.